Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Intercept's Ocaliva Eyes Vacant Ground In Europe

Executive Summary

Intercept is gearing for launch in Europe following the CHMP's positive opinion for Ocaliva (obeticholic acid) as a treatment for primary biliary cholangitis, an indication for which there is currently only one approved medication in Europe.


Related Content

Intercept Seeks Long-Term Data To Build Ocaliva Market In PBC


Related Companies